Moderna stock spikes on hantavirus research
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- WHO flagged a hantavirus outbreak on May 2 after passengers on the Dutch‑flagged cruise ship MV Hondius contracted the Andes virus, reporting eight cases, three deaths and five confirmed hantavirus infections, yet assessed the public‑health risk as low.
- Moderna’s shares rose to $59.48 before settling up less than 1 % after it announced pre‑clinical research on hantavirus in partnership with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID).
- Evercore ISI warned that the Moderna stock surge is sentiment‑driven, noting the hantavirus market is low‑incidence and unlikely to generate meaningful revenue for the company.
- Novavax dropped 5 % as Inovio fell 1 % and Emergent slipped 1 % after the initial hype faded.
- Trump said the cruise‑ship outbreak is “under control” and promised a full report, adding political reassurance to the health news.
Why it matters: Moderna’s stock gained under 1 % but analysts see no revenue, while Novavax, Inovio and Emergent each lost up to 5 % as hype faded, showing investors’ sensitivity to health‑crisis headlines and the limited commercial upside of rare‑disease markets.
